https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2023-11-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-11-20T16:42:51.08Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Tumours: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether NICE assessments of rare tumour type treatments consider both the failure rate of radiotherapy and the success rate of new treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "2190"}
, {"_about" : "http://data.parliament.uk/resources/1670388", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1670388/answer", "answerText" : {"_value" : "The NHS Long Term Plan set an ambition that, by 2028, the proportion of cancers diagnosed at stages 1 and 2 will rise from around half now to three-quarters of cancer patients. Achieving this will mean that, from 2028, 55,000 more people each year will survive their cancer for at least five years after diagnosis. Due to the nature of the ambition, this only includes stageable cancers.<\/p>
To find and diagnosed all cancers earlier, NHS England is streamlining cancer pathways to support diagnosis within 28 days by implementing non-symptom specific (NSS) pathways for patients who present with non-specific symptoms that can indicate several cancers, as well as implementing timed cancer pathways.<\/p>
Since 2019, cancer alliances have been developing new dedicated urgent diagnostic pathways for these patients so that every cancer patient with concerning, but non-specific symptoms, gets the right tests at the right time in as few visits as possible. By March 2024, the NSS programme will achieve full population coverage across England for non-specific symptom pathways as set out in the 2023/24 NHS Planning Guidance.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2023-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-11-22T11:10:53.107Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Diagnosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will take steps to ensure non-stageable cancers are included in the NHS early diagnosis target.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "2191"}
, {"_about" : "http://data.parliament.uk/resources/1670389", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1670389/answer", "answerText" : {"_value" : "
The Government will soon publish a full response to the Lord O\u2019Shaughnessy independent review into commercial clinical trials.<\/p>
The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023 as well as all other recommendations in the review.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2023-11-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-11-21T16:03:12.407Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Commercial Clinical Trials in the UK Review"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department has taken to implement the (a) significant actions under problem statement 6 and (b) other recommendations of the Lord O'Shaughnessy review of commercial clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "2192"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}